Dendreon Gets Published in NEJM
Dendreon (NASDAQ: DNDN), the Seattle-based developer of immune-boosting therapies for cancer, said today that the New England Journal of Medicine has published results from the study of 512 men with prostate cancer that led to the FDA approval of sipuleucel-T (Provenge). The study showed Provenge could extend lifespan with minimal side effects back in April 2009, and details were presented publicly at the American Urological Association meeting that month. The drug was cleared for sale by the FDA almost exactly a year later. For a couple different takes on what others have to say about today’s NEJM paper, read Matt Herper’s story at Forbes or Adam Feuerstein at TheStreet.com.